TBT is developing 4 products for a variety of indications.  Our lead asset has had successful proof of concept data in first in human studies for 3 indications, and numerous animal studies for others. Using the 505(b)(2) path, which allows for the use of non-sponsor collected data in FDA submissions,  greatly reduces the time to market.  We are gearing for Phase II trials for 3 indications.